Multidrug-resistant tuberculosis and quality-assured medicines

The Lancet

Volumn 374, Issue 9686, 2009, Pages 292-

  Barber, Sarah L ^a   Smid, Milan ^b   Hennig, Cornelia ^a   Huang, Baobin ^a   Arifaj, Dardane ^c  

^a WHO China ^*  (China)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c Western Pacific Regional Office   (Philippines)

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

DRUG BIOAVAILABILITY; DRUG QUALITY; GOOD MANUFACTURING PRACTICE; LETTER; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; TREATMENT FAILURE; WORLD HEALTH ORGANIZATION;

EID: 67651017998     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61366-0     Document Type: Letter

References (5)

1. Wright A., Zignol M., Van Deun A., et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 373 (2009) 1861-1873
2. Kelesidis T., Kelesidis I., Rafailidis P.I., and Falagas M.E. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. J Antimicrob Chemother 60 (2007) 214-236
3. Primo-Carpenter J., and McGinnis M. Matrix of drug quality reports in USAID-assisted countries (2006), US Pharmacopeia, Rockville. http://pdf.usaid.gov/pdf_docs/PNADL275.pdf (accessed July 8, 2009).
4. Caudron J.M., Ford N., Henkens M., Macé C., Kiddle-Monroe R., and Pinel J. Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop Med Int Health 13 (2008) 1062-1072
5. Cheng M.H. Ministerial meeting agrees plan for tuberculosis control. Lancet 373 (2009) 1328